Publications by authors named "Adam Reisman"
Objectives: The aim of this study was to determine the prevalence and prognostic impact of high bleeding risk (HBR), as determined by the Academic Research Consortium HBR criteria, in real-world patients undergoing left main (LM) percutaneous coronary intervention (PCI).
Background: LM PCI is often reserved for patients at increased risk for periprocedural adverse events. Patients at HBR represent a relevant percentage of this cohort, but their outcomes after LM PCI are still poorly investigated.
Article Synopsis
- Low levels of high-density lipoprotein (HDL) have been linked to negative heart-related events, but its specific impact after PCI is not well-studied.
- Researchers analyzed data from over 10,000 patients who underwent PCI between 2012 and 2017, categorizing them by HDL levels to assess 1-year major adverse cardiovascular events (MACE).
- The study found that while reduced HDL levels were associated with a higher rate of target vessel revascularization, the overall risk of major cardiovascular events was not significantly different between patients with reduced and non-reduced HDL, especially in females.
Introduction: Mitral valve repair has been established as the preferred treatment option in the management of degenerative mitral valve disease. Compared with other surgical treatment options, mitral valve repair is associated with increased survival and decreased rates of both complications and reoperations. However, among patients undergoing mitral valve repair, little is known about the predictors of postoperative outcomes.
View Article and Find Full Text PDF"Lipase Only, Please": Reducing Unnecessary Amylase Testing.
Jt Comm J Qual Patient Saf
November 2019
Background: Serum amylase testing is not recommended for the workup of acute pancreatitis; yet it is commonly ordered in acute care settings.
Methods: This was a student-led quality improvement initiative with application of a pre-post study design at two urban hospitals: Mount Sinai Hospital, a 1,134-bed academic hospital, and Mount Sinai Queens, a 235-bed community hospital. The multifaceted intervention combined a targeted educational and awareness campaign with the decoupling of amylase from electronic order sets (at the academic hospital only), as well as a nonintrusive electronic medical record (EMR) advisory statement (at both hospitals).
Objective: After finding that the thienopyridines clopidogrel and prasugrel reduced migraine headache (MHA) symptoms in some patients with patent foramen ovale (PFO), this small pilot study was undertaken to determine whether ticagrelor, a nonthienopyridine P2Y12 inhibitor, would have similar MHA effects and might be better suited for a future randomized trial.
Methods: MHA patients were screened for PFO. Participants with documented right to left shunt (RLS) and ≥6 monthly MHA days received ticagrelor therapy for 28 days.